1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Gerresheimer AG
  6. News
  7. Summary
    GXI   DE000A0LD6E6


Delayed Xetra  -  11:35 2022-07-04 am EDT
57.15 EUR   -1.38%
04:02aGERRESHEIMER AG : Gerresheimer signs new credit facility in the amount of 150 million Euro
06/30GERRESHEIMER AG : Deutsche Bank reiterates its Buy rating
06/23GERRESHEIMER AG : Berenberg gives a Buy rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gerresheimer : The leading supplier of injection vials Gerresheimer expands production in Wertheim

01/27/2022 | 10:22am EDT
  • Investment increases production in Wertheim by 150 million vials and creates 70 new jobs
  • Next step on the way to becoming the world's leading producer of glass vials
  • CEO Siemssen: "Consistent implementation of our growth strategy".

Düsseldorf/Wertheim, 27. January 2022. Gerresheimer is expanding its capacities for glass vials at the Wertheim site and at two further sites in China and the USA. The company is investing in production in Wertheim to increase vials capacity by 150 million vials per year and plans to create 70 new jobs for this purpose. The Federal Ministry of Economy and Climate Action supports the investment within the framework of federal funding of production equipment of borosilicate tubular glass and glass vials for use in vaccine production.

Gerresheimer is already one of the world's largest manufacturers of the products required for vaccination campaigns, among other things. Until now, the company has primarily served the European demand for vials from its plants in Boleslawiec (Poland) and Chalon (France). The investment will make the Wertheim plant one of the leading vial production sites in Europe.

Dietmar Siemssen, CEO of Gerresheimer AG, emphasizes the importance of the production expansion: "We already produce almost a third of the world's glass vials worldwide. With the expansion of our global capacities we are consistently implementing our growth strategy. By the end of 2022, we will be the world's leading producer of glass vials and manufacture the highest-quality and most innovative products."

The German Federal Ministry for Economic Affairs and Climate Action is supporting the investment in Wertheim. By expanding its production capacity in Wertheim, Gerresheimer is making an important contribution to improving the supply of glass vials to European vaccine manufacturers, among other things. The technology used in Wertheim enables vials to be produced in GX-Elite quality. With their outstanding cosmetic and dimensional properties, vials made of this glass lead to significantly better results in the filling of vaccines by Gerresheimer's customers. They also feature increased strength compared to standard vials. Gerresheimer has significantly increased its production capacities for vials. Compared to the level before the pandemic, they are now almost 50 percent higher. As a supplier of critical healthcare infrastructure, the company is a reliable partner for the pharma and biotech industry as well as for national and international governments. In the long term, Gerresheimer's management expects an increasing demand for drugs which have to be injected - and therefore a higher demand for vials. The global pandemic has highlighted the importance of a reliable and high-quality supply of injection solutions.

More info:
Gerresheimer glass vials/glass bottles

Contact Press
Ueli Utzinger
Group Senior Director Communication & Marketing
T +49 211 6181-250

Contact IR
Carolin Nadilo
Corporate Senior Director Investor Relations
T +49 211 6181-220

About Gerresheimer

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.


Gerresheimer AG published this content on 27 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 January 2022 15:21:02 UTC.

© Publicnow 2022
All news about GERRESHEIMER AG
04:02aGERRESHEIMER AG : Gerresheimer signs new credit facility in the amount of 150 million Euro
06/30GERRESHEIMER AG : Deutsche Bank reiterates its Buy rating
06/23GERRESHEIMER AG : Berenberg gives a Buy rating
06/23GERRESHEIMER AG : Deutsche Bank gives a Buy rating
06/22GERRESHEIMER AG : JP Morgan reiterates its Neutral rating
06/15GERRESHEIMER AG : Gets a Buy rating from DZ Bank
06/14GERRESHEIMER AG : Receives a Buy rating from Credit Suisse
06/13Gerresheimer Partners with Medtech Start-Up Adamant Health to Revolutionize Treatment o..
06/13GERRESHEIMER AG : Gerresheimer partners with MedTech start-up Adamant Health to revolution..
06/13Adamant Health Oy announced that it has received €2.2 million in funding from Gerr..
More news
Analyst Recommendations on GERRESHEIMER AG
More recommendations
Sales 2022 1 696 M 1 768 M 1 768 M
Net income 2022 114 M 119 M 119 M
Net Debt 2022 1 052 M 1 097 M 1 097 M
P/E ratio 2022 15,8x
Yield 2022 2,33%
Capitalization 1 795 M 1 871 M 1 871 M
EV / Sales 2022 1,68x
EV / Sales 2023 1,55x
Nbr of Employees 10 625
Free-Float 100%
Duration : Period :
Gerresheimer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 8
Last Close Price 57,15 €
Average target price 91,54 €
Spread / Average Target 60,2%
EPS Revisions
Managers and Directors
Dietmar Siemssen Chief Executive Officer
Bernd Metzner Chief Financial Officer
Axel Herberg Chairman-Supervisory Board
Theodor Stuth Member-Supervisory Board
Udo Johannes Vetter Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC-11.67%121 417